Lenox Wealth Management’s Cytokinetics CYTK Stock Holding History

Lenox Wealth Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-650	Closed	-$4K	–	580
2018 Q1	$4K	Hold	650	–	–	﹤0.01%	409
2017 Q4	$5K	Hold	650	–	–	﹤0.01%	420
2017 Q3	$9K	Hold	650	–	–	﹤0.01%	405
2017 Q2	$8K	Hold	650	–	–	﹤0.01%	394
2017 Q1	$8K	Hold	650	–	–	0.01%	173
2016 Q4	$8K	Hold	650	–	–	0.01%	174
2016 Q3	$6K	Hold	650	–	–	﹤0.01%	176
2016 Q2	$6K	Hold	650	–	–	﹤0.01%	181
2016 Q1	$5K	Hold	650	–	–	﹤0.01%	188
2015 Q4	$7K	Hold	650	–	–	0.01%	178
2015 Q3	$4K	Hold	650	–	–	﹤0.01%	130
2015 Q2	$4K	Hold	650	–	–	﹤0.01%	136
2015 Q1	$4K	Hold	650	–	–	﹤0.01%	139
2014 Q4	$5K	Hold	650	–	–	﹤0.01%	138
2014 Q3	$2K	Hold	650	–	–	﹤0.01%	150
2014 Q2	$3K	Buy	650 +500	+333%	+$3.05K	﹤0.01%	150
2014 Q1	$1K	Hold	150	–	–	﹤0.01%	175
2013 Q4	$1K	Buy	+150	New	+$985	﹤0.01%	176

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LPU

Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Lenox Wealth Management's CYTK Position: Q2 2018 in Review

Lenox Wealth Management sold out of Cytokinetics (CYTK) in Q2 2018, closing a stake of 650 shares — an estimated $4K sold.

Lenox Wealth Management first reported a position in CYTK in Q4 2013 and held it in 18 quarters. The position peaked at $9K in Q3 2017. 126 funds tracked by Wall St. Rank hold CYTK as of Q2 2018.

Lenox Wealth Management reported no remaining Cytokinetics position as of Q2 2018 after selling out during the quarter.
Lenox Wealth Management sold 650 Cytokinetics shares in Q2 2018, an estimated $4K.
Lenox Wealth Management first reported a position in Cytokinetics in Q4 2013 and held it in 18 quarters.
Lenox Wealth Management's Cytokinetics position peaked at $9K in Q3 2017.
126 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2018.

Based on Lenox Wealth Management's 13F filing for Q2 2018, filed 26 Jul 2018.